All these findings are consistent with the literature as CD4, CD8, FoxP3, and PD1 are inflammation markers, and POLE-mutated endometrial carcinomas, usually with a better prognosis than POLE WT, with higher abundance of A1 areas, are described to have large lymphocyte populations (Li et al., 2019b). The gene discussed is CD8A; the disease is endometrial carcinoma.